94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Kunping Li1†
Yuqing Li1†Yinfeng Lyu1†Linyi Tan1Xinyi Zheng2Haowen Jiang1*Hui Wen1*
Chenchen Feng1,2,3*- 1Department of Urology, Huashan Hospital, Fudan University, Shanghai, China
- 2Department of Pharmacology, Huashan Hospital, Fudan University, Shanghai, China
- 3Beijing Advanced Innovation Center for Food Nutrition and Human Health, Beijing Technology and Business University (BTBU), Beijing, China
A Corrigendum on:
Development of a phagocytosis-dependent gene signature to predict prognosis and response to checkpoint inhibition in clear-cell renal cell carcinoma
by Li K, Li Y, Lyu Y, Tan L, Zheng X, Jiang H, Wen H and Feng C (2022) 13:853088. doi: 10.3389/fimmu.2022.853088
In the published article, there was an error in the author contributions, and author Yinfeng Lyu should be added a token indicating equal contribution Yinfeng Lyu†. The corrected author list appears below.
Kunping Li 1†, Yuqing Li 1†, Yinfeng Lyu 1†, Linyi Tan 1, Xinyi Zheng 2, Haowen Jiang 1*, Hui Wen 1* and Chenchen Feng 1,2,3,*
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: clear-cell renal cell carcinoma, antibody-dependent cellular phagocytosis, immune checkpoint inhibition, biomarker, bioinformatics
Citation: Li K, Li Y, Lyu Y, Tan L, Zheng X, Jiang H, Wen H and Feng C (2023) Corrigendum: Development of a phagocytosis- dependent gene signature to predict prognosis and response to checkpoint inhibition in clear-cell renal cell carcinoma. Front. Immunol. 14:1140764. doi: 10.3389/fimmu.2023.1140764
Received: 09 January 2023; Accepted: 10 January 2023;
Published: 19 January 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Li, Li, Lyu, Tan, Zheng, Jiang, Wen and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hui Wen, ZHJ3ZW5odWlAMTYzLmNvbQ==; Haowen Jiang, ZHJqaWFuZ2hhb3dlbkAxNjMuY29t; Chenchen Feng, ZHJmZW5nY2hlbmNoZW5AMTYzLmNvbQ==
†These authors have contributed equally to this work